You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBevantolol
Accession NumberDB01295
TypeSmall Molecule
GroupsApproved
DescriptionBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Structure
Thumb
Synonyms
(+-)-Bevantolol
1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol
1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol
1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol
1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol
Bevantololum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII34ZXW6ZV21
CAS number59170-23-9
WeightAverage: 345.4327
Monoisotopic: 345.194008357
Chemical FormulaC20H27NO4
InChI KeyInChIKey=HXLAFSUPPDYFEO-UHFFFAOYSA-N
InChI
InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
IUPAC Name
1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
SMILES
COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassMethoxybenzenes
Direct ParentDimethoxybenzenes
Alternative Parents
Substituents
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • Phenethylamine
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Toluene
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of angina pectoris and hypertension.
PharmacodynamicsBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
Mechanism of actionAnimal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bevantolol Action PathwayDrug actionSMP00668
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8271
Blood Brain Barrier-0.9297
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.8119
P-glycoprotein inhibitor IInhibitor0.625
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterNon-inhibitor0.6935
CYP450 2C9 substrateNon-substrate0.7741
CYP450 2D6 substrateSubstrate0.5792
CYP450 3A4 substrateSubstrate0.5727
CYP450 1A2 substrateNon-inhibitor0.6261
CYP450 2C9 inhibitorNon-inhibitor0.9068
CYP450 2D6 inhibitorNon-inhibitor0.7311
CYP450 2C19 inhibitorNon-inhibitor0.9218
CYP450 3A4 inhibitorNon-inhibitor0.6133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9339
Ames testNon AMES toxic0.9124
CarcinogenicityNon-carcinogens0.926
BiodegradationNot ready biodegradable0.8696
Rat acute toxicity2.0966 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6187
hERG inhibition (predictor II)Inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point137-138 °CPhysProp
logP3.00HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP2.83ALOGPS
logP3.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity98.54 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yutaka Nomura, “Process for preparation of bevantolol hydrochloride.” U.S. Patent US5382689, issued December, 1974.

US5382689
General References
  1. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789 ]
External Links
ATC CodesC07AB06C07BB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Bevantolol.
AcepromazineAcepromazine may increase the hypotensive activities of Bevantolol.
AcetohexamideBevantolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Acetylcholine.
AcetyldigitoxinBevantolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bevantolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Bevantolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
AlfuzosinBevantolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Bevantolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Bevantolol.
AmiodaroneAmiodarone may increase the bradycardic activities of Bevantolol.
AmobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Amobarbital.
AmodiaquineThe metabolism of Bevantolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Bevantolol can be increased when it is combined with Amoxapine.
AntipyrineAntipyrine may decrease the antihypertensive activities of Bevantolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
ApraclonidineApraclonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
ApremilastApremilast may decrease the antihypertensive activities of Bevantolol.
ArecolineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Arecoline.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bevantolol.
AzelastineAzelastine may decrease the antihypertensive activities of Bevantolol.
BalsalazideBalsalazide may decrease the antihypertensive activities of Bevantolol.
BarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bevantolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BethanecholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Bethanechol.
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BromfenacBromfenac may decrease the antihypertensive activities of Bevantolol.
BromocriptineBevantolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bevantolol.
CabergolineBevantolol may increase the vasoconstricting activities of Cabergoline.
CarbacholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Carbachol.
CarprofenCarprofen may decrease the antihypertensive activities of Bevantolol.
CarvedilolBevantolol may increase the orthostatic hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Bevantolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Bevantolol.
CevimelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Bevantolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bevantolol.
ChlorpropamideBevantolol may increase the hypoglycemic activities of Chlorpropamide.
ClomipramineThe serum concentration of Bevantolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
ClonixinClonixin may decrease the antihypertensive activities of Bevantolol.
CoumaphosCoumaphos may increase the bradycardic activities of Bevantolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bevantolol.
DapoxetineThe serum concentration of Bevantolol can be increased when it is combined with Dapoxetine.
DecamethoniumDecamethonium may increase the bradycardic activities of Bevantolol.
DemecariumDemecarium may increase the bradycardic activities of Bevantolol.
DeslanosideBevantolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
DichlorvosDichlorvos may increase the bradycardic activities of Bevantolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Bevantolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Bevantolol.
DigitoxinBevantolol may increase the bradycardic activities of Digitoxin.
DigoxinBevantolol may increase the bradycardic activities of Digoxin.
DihydroergotamineBevantolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol.
DipyridamoleDipyridamole may increase the bradycardic activities of Bevantolol.
DisopyramideDisopyramide may increase the bradycardic activities of Bevantolol.
DonepezilDonepezil may increase the bradycardic activities of Bevantolol.
DoxazosinBevantolol may increase the orthostatic hypotensive activities of Doxazosin.
DronedaroneDronedarone may increase the bradycardic activities of Bevantolol.
DroxicamDroxicam may decrease the antihypertensive activities of Bevantolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bevantolol.
EchothiophateEchothiophate may increase the bradycardic activities of Bevantolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Bevantolol.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bevantolol.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bevantolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
EpirizoleEpirizole may decrease the antihypertensive activities of Bevantolol.
Ergoloid mesylateBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineBevantolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineBevantolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Bevantolol.
EtodolacEtodolac may decrease the antihypertensive activities of Bevantolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Bevantolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.
EtoperidoneThe serum concentration of Bevantolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bevantolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bevantolol.
exisulindexisulind may decrease the antihypertensive activities of Bevantolol.
FenbufenFenbufen may decrease the antihypertensive activities of Bevantolol.
FenfluramineThe serum concentration of Bevantolol can be increased when it is combined with Fenfluramine.
FenoprofenFenoprofen may decrease the antihypertensive activities of Bevantolol.
FenthionFenthion may increase the bradycardic activities of Bevantolol.
FingolimodBevantolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bevantolol.
FlunixinFlunixin may decrease the antihypertensive activities of Bevantolol.
FluoxetineThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Bevantolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bevantolol.
GalantamineGalantamine may increase the bradycardic activities of Bevantolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bevantolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bevantolol.
GlibornurideBevantolol may increase the hypoglycemic activities of Glibornuride.
GliclazideBevantolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideBevantolol may increase the hypoglycemic activities of Glimepiride.
GlipizideBevantolol may increase the hypoglycemic activities of Glipizide.
GliquidoneBevantolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideBevantolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideBevantolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Bevantolol is combined with GTS-21.
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bevantolol.
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
HexobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bevantolol.
Huperzine AHuperzine A may increase the bradycardic activities of Bevantolol.
HydroxychloroquineThe metabolism of Bevantolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Bevantolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Bevantolol.
IcatibantIcatibant may decrease the antihypertensive activities of Bevantolol.
IndalpineThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.
IndomethacinIndomethacin may decrease the antihypertensive activities of Bevantolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Bevantolol.
IndoraminBevantolol may increase the orthostatic hypotensive activities of Indoramin.
Insulin PorkBevantolol may increase the hypoglycemic activities of Insulin Pork.
IsoflurophateIsoflurophate may increase the bradycardic activities of Bevantolol.
IsoxicamIsoxicam may decrease the antihypertensive activities of Bevantolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Bevantolol.
KetoprofenKetoprofen may decrease the antihypertensive activities of Bevantolol.
KetorolacKetorolac may decrease the antihypertensive activities of Bevantolol.
LabetalolBevantolol may increase the orthostatic hypotensive activities of Labetalol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Bevantolol.
LevomilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bevantolol.
LobelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline.
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
LornoxicamLornoxicam may decrease the antihypertensive activities of Bevantolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bevantolol.
Lu AA21004The serum concentration of Bevantolol can be increased when it is combined with Lu AA21004.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bevantolol.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.
MalathionMalathion may increase the bradycardic activities of Bevantolol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Bevantolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bevantolol.
MefloquineMefloquine may increase the bradycardic activities of Bevantolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Bevantolol.
MemantineMemantine may increase the bradycardic activities of Bevantolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.
MesalazineMesalazine may decrease the antihypertensive activities of Bevantolol.
MesoridazineMesoridazine may increase the hypotensive activities of Bevantolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Bevantolol.
MethacholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Methacholine.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
MethohexitalThe serum concentration of Bevantolol can be decreased when it is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bevantolol.
Methylene blueMethylene blue may increase the hypotensive activities of Bevantolol.
MethylphenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital.
MidodrineBevantolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Bevantolol.
MoricizineMoricizine may increase the hypotensive activities of Bevantolol.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bevantolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Bevantolol.
NaftifineNaftifine may decrease the antihypertensive activities of Bevantolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.
NaproxenNaproxen may decrease the antihypertensive activities of Bevantolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bevantolol.
NeostigmineNeostigmine may increase the bradycardic activities of Bevantolol.
NepafenacNepafenac may decrease the antihypertensive activities of Bevantolol.
NicotineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Bevantolol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bevantolol.
NimesulideNimesulide may decrease the antihypertensive activities of Bevantolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
OlanzapineThe serum concentration of Bevantolol can be increased when it is combined with Olanzapine.
OlopatadineOlopatadine may decrease the antihypertensive activities of Bevantolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Bevantolol.
OrgoteinOrgotein may decrease the antihypertensive activities of Bevantolol.
OuabainBevantolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Bevantolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bevantolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Bevantolol.
ParoxetineThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bevantolol.
PerphenazinePerphenazine may increase the hypotensive activities of Bevantolol.
PhenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bevantolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
PhysostigminePhysostigmine may increase the bradycardic activities of Bevantolol.
PilocarpineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bevantolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Bevantolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Bevantolol.
PrazosinBevantolol may increase the orthostatic hypotensive activities of Prazosin.
PrimaquineThe metabolism of Bevantolol can be decreased when combined with Primaquine.
PrimidoneThe serum concentration of Bevantolol can be decreased when it is combined with Primidone.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bevantolol.
PromazinePromazine may increase the hypotensive activities of Bevantolol.
PromethazinePromethazine may increase the hypotensive activities of Bevantolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Bevantolol.
PropafenoneThe serum concentration of Bevantolol can be increased when it is combined with Propafenone.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
PTC299PTC299 may decrease the antihypertensive activities of Bevantolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Bevantolol.
RegorafenibRegorafenib may increase the bradycardic activities of Bevantolol.
ReserpineReserpine may increase the hypotensive activities of Bevantolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Bevantolol.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.
RivastigmineRivastigmine may increase the bradycardic activities of Bevantolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Bevantolol.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bevantolol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Bevantolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bevantolol.
SalsalateSalsalate may decrease the antihypertensive activities of Bevantolol.
SecobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.
SeratrodastSeratrodast may decrease the antihypertensive activities of Bevantolol.
SertralineThe serum concentration of Bevantolol can be increased when it is combined with Sertraline.
SilodosinBevantolol may increase the orthostatic hypotensive activities of Silodosin.
SRT501SRT501 may decrease the antihypertensive activities of Bevantolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bevantolol.
SulindacSulindac may decrease the antihypertensive activities of Bevantolol.
SuprofenSuprofen may decrease the antihypertensive activities of Bevantolol.
TacrineTacrine may increase the bradycardic activities of Bevantolol.
TamsulosinBevantolol may increase the orthostatic hypotensive activities of Tamsulosin.
TenoxicamTenoxicam may decrease the antihypertensive activities of Bevantolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Bevantolol.
TerazosinBevantolol may increase the orthostatic hypotensive activities of Terazosin.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bevantolol.
ThiamylalThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bevantolol.
ThiopentalThe serum concentration of Bevantolol can be decreased when it is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Bevantolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
TolazamideBevantolol may increase the hypoglycemic activities of Tolazamide.
TolbutamideBevantolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.
TolmetinTolmetin may decrease the antihypertensive activities of Bevantolol.
TranilastTranilast may decrease the antihypertensive activities of Bevantolol.
TrazodoneThe serum concentration of Bevantolol can be increased when it is combined with Trazodone.
TrichlorfonTrichlorfon may increase the bradycardic activities of Bevantolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bevantolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Bevantolol.
TrimazosinBevantolol may increase the orthostatic hypotensive activities of Trimazosin.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bevantolol.
TubocurarineTubocurarine may increase the bradycardic activities of Bevantolol.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bevantolol.
VareniclineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Varenicline.
VilazodoneThe serum concentration of Bevantolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Bevantolol can be increased when it is combined with Vortioxetine.
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bevantolol.
ZileutonZileuton may decrease the antihypertensive activities of Bevantolol.
ZimelidineThe serum concentration of Bevantolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Bevantolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8. [PubMed:2568629 ]
  2. Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. [PubMed:2858236 ]
  3. Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. [PubMed:6148733 ]
  4. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789 ]
  5. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 08:18 / Updated on August 17, 2016 12:23